NASDAQ:NTEC Intec Pharma (NTEC) Stock Price, News & Analysis → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free NTEC Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$9.15▼$36.2052-Week Range N/AVolume988,300 shsAverage Volume543,436 shsMarket Capitalization$8.65 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Intec Pharma alerts: Email Address Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). About Intec Pharma Stock (NASDAQ:NTEC)Intec Pharma Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvika Joseph on October 23, 2000 and is headquartered in Jerusalem, Israel.Read More Ad Stansberry Research“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.Find out why right here (and see what you can do to get in too with just a few dollars). NTEC Stock News HeadlinesMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for Indaptus Therapeutics Amid Positive Clinical and Financial OutlookMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed on Indaptus Therapeutics as Decoy20 Advances in Phase 1 with Promising DevelopmentsApril 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.February 18, 2024 | msn.comStocks to Watch Today: RVNL,Glenmark Pharma, PB Fintech,Sula Vineyards and moreFebruary 2, 2024 | msn.comChhattisgarh education minister calls for expansion of central schools in the stateAugust 15, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Buy Rating for Indaptus Therapeutics (INDP)June 16, 2023 | finance.yahoo.comNGENF - NervGen Pharma Corp.May 12, 2023 | marketwatch.com10-Q: INDAPTUS THERAPEUTICS, INC.April 26, 2024 | Stansberry Research (Ad)“Retirement Secret” Showed 995% Gain Last Time We Shared ItCentral Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers.May 10, 2023 | marketwatch.comFibromyalgia Treatment Market Research | 2023-2030May 9, 2023 | marketwatch.comEarly Pregnancy Test Kit Market May Set Epic Growth Story Major Players – Abbott, Church & Dwight, SPD Swiss Precision Diagnostics GmbHMay 4, 2023 | marketwatch.comFibromyalgia Treatment Market Share, Size, Financial Summaries Analysis from 2023 to 2028April 28, 2023 | marketwatch.comFibromyalgia Treatment Market Share by 2031April 24, 2023 | ca.finance.yahoo.comIntec Pharma Ltd (5NU.SG)March 30, 2023 | marketwatch.comFibromyalgia Treatment Market Size, Share, Outlook and Forecast to 2031March 18, 2023 | markets.businessinsider.comMaxim Group Reaffirms Their Buy Rating on Indaptus Therapeutics (INDP)March 2, 2023 | marketwatch.comFibromyalgia Treatment Market Forecast: An Analysis of Industry Trends for 2023-2028February 19, 2023 | marketwatch.comGlobal Parkinson’s Disease Treatment Market Opportunities, Business Statistics Research Report 2030 By VMReportsFebruary 15, 2023 | marketwatch.comFibromyalgia Treatment Market Size 2023 With Over-All Dominated, Share Of Everywhere, Ease Of Access Of SolutionsJanuary 30, 2023 | marketwatch.comSyphilis Rapid Test Kit Market : Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2028January 23, 2023 | marketwatch.comFibromyalgia Treatment Market Industry Updates, New Opportunities, Major Strategies, And Forecast 2028December 29, 2022 | marketwatch.comWith 1.7% CAGR, Fibromyalgia Treatment Market 2023 Is Flourishing Around the World by 2028 | 116 Pages ReportDecember 21, 2022 | marketwatch.comFibromyalgia Treatment Market (New Report) to Witness A Pronounce Growth During 2023-2028 | 116 Pages ReportOctober 17, 2022 | marketwatch.comFibromyalgia Treatment Market Size in 2022 with Latest Report of 100 Pages & Business Forecast up to 2028 by Value Chain Analysis | No of Pages 100August 28, 2022 | marketwatch.comFibromyalgia Treatment Market Size and Share 2022 Analysis Report by Industry Trends, Drivers, Applications, Sale and Forecast to 2028July 5, 2022 | investing.comWorld Holdings Co Ltd (2429)June 4, 2022 | finanznachrichten.deBeroe Inc.: Beroe partners with Mintec to power its intelligence offering with market-leading commodity price dataSee More Headlines Receive NTEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intec Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/17/2021Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:NTEC CUSIPN/A CIK1638381 Webwww.intecpharma.com Phone(722) 586-4657FaxN/AEmployees40Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($16.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-96.37% Return on Assets-68.87% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$16.18 per share Price / BookN/AMiscellaneous Outstanding Shares898,000Free FloatN/AMarket Cap$8.65 million OptionableOptionable Beta0.83 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesJeffrey A. MecklerVice Chairman & Chief Executive OfficerNir SassiPresident & Chief Financial OfficerMichael James NewmanDirector & Chief Scientific OfficerAnna Hotovely-SalomonDirector-Clinical AffairsWalt A. LinscottChief Business OfficerKey CompetitorsNuCanaNASDAQ:NCNAMolecular TemplatesNASDAQ:MTEMVirios TherapeuticsNASDAQ:VIRICyclerion TherapeuticsNASDAQ:CYCNHepion PharmaceuticalsNASDAQ:HEPAView All Competitors NTEC Stock Analysis - Frequently Asked Questions How were Intec Pharma's earnings last quarter? Intec Pharma Ltd (NASDAQ:NTEC) announced its quarterly earnings data on Monday, May, 17th. The biotechnology company reported ($3.84) earnings per share for the quarter, missing the consensus estimate of ($3.48) by $0.36. When did Intec Pharma's stock split? Shares of Intec Pharma reverse split on Tuesday, July 27th 2021. The 1-4 reverse split was announced on Tuesday, July 27th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 27th 2021. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split. What other stocks do shareholders of Intec Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Intec Pharma investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Nabriva Therapeutics (NBRV), Onconova Therapeutics (ONTX), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), T2 Biosystems (TTOO) and Acasti Pharma (ACST). When did Intec Pharma IPO? Intec Pharma (NTEC) raised $30 million in an IPO on Tuesday, August 4th 2015. The company issued 5,000,000 shares at a price of $6.00 per share. Maxim Group and Roth Capital Partners acted as the underwriters for the IPO. This page (NASDAQ:NTEC) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchThe only accurate crypto trading system I know …Weiss RatingsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intec Pharma Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
